Company news

Nurix Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

October 31, 2023

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

October 11, 2023

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

September 6, 2023

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

July 12, 2023

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

June 13, 2023

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 8, 2023

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

April 16, 2023

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

April 12, 2023

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

March 19, 2023

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

March 13, 2023

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 5, 2023

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

February 8, 2023

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

January 8, 2023

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

December 14, 2022

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

December 11, 2022

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

December 6, 2022

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

November 9, 2022

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

November 9, 2022

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

November 2, 2022

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

October 25, 2022

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

October 18, 2022

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

October 5, 2022

Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

October 4, 2022

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

September 13, 2022

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

August 2, 2022

Nurix Therapeutics Announces $40 Million Registered Direct Offering

July 7, 2022

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

July 6, 2022

Nurix Therapeutics Announces $55 Million Registered Direct Offering

July 6, 2022

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

June 29, 2022

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

June 9, 2022

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

June 2, 2022

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

May 25, 2022

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

May 16, 2022

Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

May 10, 2022

Nurix Therapeutics to Host R&D Day on May 26, 2022

May 8, 2022

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

April 7, 2022

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

April 6, 2022

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

April 4, 2022

Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

April 3, 2022

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

March 28, 2022

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

March 7, 2022

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

January 26, 2022

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

January 9, 2022

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

December 11, 2021

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

November 11, 2021

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

November 11, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 32 decks. Every deck is listed under its year.